Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + vinorelbine + ifosfamide + filgrastim
- Development stage
- Unknown
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
The combination of gemcitabine, vinorelbine, ifosfamide, and filgrastim is a multi-agent chemotherapy regimen primarily used as salvage therapy for relapsed or refractory Hodgkin lymphoma and other lymphomas. Gemcitabine is a nucleoside analog that inhibits DNA synthesis; vinorelbine is a vinca alkaloid that disrupts microtubule formation; ifosfamide is an alkylating agent causing DNA cross-linking and cell death; filgrastim (recombinant human granulocyte colony-stimulating factor) stimulates neutrophil production to reduce the risk of neutropenia associated with intensive chemotherapy. This regimen (often called IGEV when prednisolone is included) has demonstrated efficacy in inducing remission and facilitating stem cell mobilization prior to autologous transplantation in patients with poor prognosis or relapsed disease[1][4][5][7].
- Other names
- IGEV regimen
02
Targets
DNADNA polymerase familyCSF3R (Granulocyte colony-stimulating factor receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + vinorelbine + ifosfamide + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + vinorelbine + ifosfamide + filgrastim.